<DOC>
	<DOCNO>NCT03073577</DOCNO>
	<brief_summary>Islet Transplantation procedure use people difficult control Type 1 Diabetes . Insulin produce cell ( islet ) isolate deceased donor pancreas . After cell carefully isolate donor pancreas , islet transplant recipient 's liver . These transplanted islet may produce insulin . One challenge islet transplant death transplant islet due inflammation , oxidative stress exposure diabetogenic immunosuppressive agent associate islet functional impairment graft loss , especially link use calcineurin inhibitor , include tacrolimus ( Tac ) . Antiaging glycopeptide ( PKX-001 ) small , stable , synthetic replica antifreeze protein ( AFPs ) , naturally occur Arctic Antarctic fish show protect cell harmful condition . PKX-001 new drug show lab study help islet cell survive isolation keep healthy functioning . Most importantly , animal study show islet treat PKX-001 protect immunosuppressant ( Tac ) toxicity retain function animal receive islet transplant . This study involve 10 participant islet transplant wait list Clinical Islet Transplant Program . All participant receive islet treat medication PKX-001 . PKX-001 use islet preservation process , give participant medication . The purpose study confirm safety transplantation PKX-001 treat islet evaluate cytoprotective capacity PKX-001 islet transplantation , especially capacity protect Tac induce graft dysfunction .</brief_summary>
	<brief_title>Islet Transplantation Using PKX-001</brief_title>
	<detailed_description>Background Clinical islet transplantation today accept modality treat select diabetic patient frequent hypoglycemic event severe glycemic liability . Although islet transplantation outcome improve significantly highly specialized center 5-year insulin independence rate exceed 50 % , proportion patient require reintroduction insulin later . Tac may partly responsible limited islet durability need multiple donor recipient spite ability prevent rejection autoimmune recurrence . In vitro study islet expose immunosuppressant show Tac level 10-100 mg/L cause vacuolization destruction islet culture . Antifreeze protein ( AFPs ) generate considerable interest ability protect cell variety condition . However , large size restricts use medicine unable pas capillary interstitial tissue unable reach target cell . With disadvantage AFPs mind , Dr. Geraldine-Castelot-Deliencourt ( Rouen , France ) invent Antiaging glycopeptide , later manufacture ProtoKinetix Inc. ( St. Marys , West Virginia , US ) . ProtoKinetix ' anti-aging glycopeptide , PKX-001 , small , stable , synthetic replica large , less stable AFP . PKX-001 go series test various outsourced laboratory Europe North America . These test prove ability protect multitude cell line ( Hela cell , adult fibroblast , neonatal fibroblast , human neuronal stem cell , mouse neuronal stem cell , mouse islet cell , blood platelet , cluster differentiation 34+ ( CD34+ ) cell , keratinocytes ) ultraviolet A ( UVA ) , ultraviolet C ( UVC ) , Hydrogen Peroxide , Inflammatory ( ILβ ) , Time , Temperature ( -196°C , -80°C , -3°C , 3°C , 4°C , 15°C 22°C ) Low Serum induce cell death pHs 5.3 -10.5 . In addition protect cell survival PKX-001 also preserve cell functionality . This tested via stem cell marker , CD34+ functionality test , vivo study PKX-001 treat transplanted islet cell find reduce blood glucose concentration diabetic mice 40 % day 40 comparison islet cell transplant mouse without first expose PKX-001 . In light beneficial role PKX-001 cellular survival functionality preservation , team evaluate cytoprotective capacity PKX-001 islet transplant , especially capacity protection diabetogenic effect Tac . In vitro assessment human islet culture PKX-001 supplementation also show enhanced quality yield post-preservation human islet protection acute exposure Tac clinical relevant dos compare without PKX-001 supplementation . Further analysis indicate islet treat PKX-001 decrease oxidative stress , improve insulin release increase islet exocytosis , decreased islet loss preservation due apoptosis , even presence Tac . In vivo study complement vitro finding , demonstrate PKX-001 supplementation suppress early inflammation improve islet engraftment long-term efficacy . The propose study phase I , non-randomized , open-label , single arm , prospective trial use retrospective control . Ten adult Islet transplant candidate ( 18 year old ) , deem appropriate standard islet transplant University Alberta Hospital enrol investigation . Retrospective data 10 islet transplant patient consent chart review ( Protocol # : 000001120 entitle : `` On-going review islet transplant patient University Alberta '' Protocol # : 000001122 entitle : `` Collaborative Islet Transplant Registry '' ) also collect . The standard Care control identify Islet Transplant program database ( period : 2014 - 2016 ) anonymized simple numbering system . Hypothesis : Transplantation PKX-001 treat islet safe improves graft outcomes . Primary Objective : To demonstrate safety transplantation PKX-001 treat islet . Secondary Objectives : To assess efficacy transplantation PKX-001 treat islet To assess efficacy addition PKX-001 islet preservation Procedures : Prior transplantation , patient screen , qualify , list transplant , sign inform consent form . At time suitable islet preparation become available , patient receive allogeneic islet cell transplant patient intraportally percutaneous transhepatic access . Islet transplant perform current immunosuppression regimen include : induction ( Alemtuzumab/Basiliximab ) long-term immunosuppression ( Prograf/Cellcept ) . The engraftment regimen include anti-inflammatory medication ( Etanercept/Anakinra ) intravenous insulin heparin . The additional intervention use pilot trial addition investigational agent , PKX-001 islet processing . Follow : Participants undergo 3-month follow-up period follow initial subsequent islet transplant . There study-specific follow-up visit require study . Study subject follow per standard care . For purpose evaluate primary secondary endpoint , follow measurement collect study subject time point indicate per standard care , chart review record Day 30 post-transplant : Clinical Assessment Transplant Fellow Staff ; Post-Transplant Blood work ( per Standard Care ) ; Metabolic testing : Ensure ( Arginine ) ; Glucose Records Self-Monitoring . Incidence Primary Non-Function ( see Glossary definition ) ; Incidence Adverse Events Serious Adverse Events report day post transplant ; Abdominal Ultrasound Doppler report ( clinically significant finding ) . The study remain open collect 10 recipient ' follow-up data 3 month post-transplant . Primary secondary outcome reporting occur 90 day follow transplant last patient trial .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>To eligible participant must type 1 diabetes mellitus ( T1DM ) 5 year , complicate least 1 follow situation persist despite intensive insulin management effort : 1 . Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 3.0 mmol/L , indicate , 1 episode severe hypoglycemia require third party assistance within 12 month , Clarke score ≥4 , hypoglycemic ( HYPO ) score ≥1,000 , lability index ( LI ) ≥400 combine HYPO/LI &gt; 400/ &gt; 300 . 2 . Metabolic instability , characterize erratic blood glucose level interfere daily activity and/or 1 hospital visit diabetic ketoacidosis last 12 month . Participants must capable understand purpose risk study must sign statement informed consent . Retrospective Control All control participant include accord immunosuppression / engraftment regimen use pilot , specifically current standard care islet transplant University Alberta Hospital : Alemtuzumab/Basiliximab , Anakinra , Etanercept , Mycophenolate Mofetil Tacrolimus . History enrollment islet transplant trial ( discretion investigator ) . Severe coexist cardiac disease , characterize one condition : ( ) recent ( within past 6months ) myocardial infarction ; ( b ) leave ventricular ejection fraction &lt; 30 % ; ( c ) evidence ischemia functional cardiac exam . Active alcohol substance abuse , include cigarette smoking ( must abstinent 6 month prior list transplant ) . Psychiatric disorder make patient suitable candidate transplantation ( e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication ) . History nonadherence prescribe regimen . Active infection include Hepatitis C , Hepatitis B , HIV , Tuberculosis ( TB ) ( subject positive purify protein derivative ( PPD ) perform within one year enrollment , history adequate chemoprophylaxis ) . Any history , current malignancy except squamous basal skin cancer . BMI &gt; 35 kg/m2 screen visit . Age le 18 great 68 year . Measured glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 . Presence history macroalbuminuria ( &gt; 300 mg/g creatinine ) . Clinical suspicion nephritic ( hematuria , active urinary sediment ) rapidly progress renal impairment ( e.g . Increase serum creatinine 25 % within last 36 month ) . Baseline Hb &lt; 105g/L ( &lt; 10.5 g/dL ) woman , &lt; 120 g/L ( &lt; 12 g/dL ) men . Baseline screen liver function test outside normal range , exception uncomplicated Gilbert 's Syndrome . An initial liver function test ( LFT ) panel value &gt; 1.5 time upper limit normal ( ULN ) exclude patient without retest ; re‑test value ULN 1.5 time ULN make , value remain elevated normal limit , patient exclude . Untreated proliferative retinopathy . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breast‑feeding . Evidence significant sensitization panel reactive antibody ( PRA ) ( discretion investigator ) . Insulin requirement &gt; 1.0 U/kg/day HbA1C &gt; 12 % . Uncontrolled hyperlipidemia [ fast LDL cholesterol &gt; 3.4 mmol/L ( 133 mg/dL ) , treat untreated ; and/or fast triglyceride &gt; 2.3 mmol/L ( 90 mg/dL ) ] . Under treatment medical condition require chronic use steroid . Use coumadin anticoagulant therapy ( except aspirin ) patient prothrombin time ( PT ) / international normalize ratio ( INR ) &gt; 1.5 . Untreated Celiac disease . Patients Graves disease exclude unless previously adequately treated radioiodine ablative therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>Islet Transplantation</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetes Treatment</keyword>
</DOC>